ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation

D. Halleran,1 S. Schurman, T. Welch, V. Whittaker.

1Surgery, State University New York Upstate Medical University, Syracuse, NY
2Pediatric Nephrology, State University New York Upstate Medical University, Syracuse, NY.

Meeting: 2015 American Transplant Congress

Abstract number: D210

Keywords: Induction therapy, Kidney transplantation, Pediatric

Session Information

Session Name: Poster Session D: Pediatric Clinical Kidney Transplantation

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day zero and post-operative day one and basiliximab (20 mg) given on day two, followed by steroid-free maintenance therapy for pediatric patients undergoing kidney transplantation.

Methods: We retrospectively reviewed 208 consecutive patients who underwent kidney transplantation from 1/1/2009 to 10/1/2014 at our institution. Patients identified as younger than 18 years old at the time of transplantation were included for comparison. 6 patients were identified in the current rATG plus basiliximab group (Cohort A), and 15 in the historical basiliximab with steroid taper group (Cohort B). Outcomes between the two groups were compared using hospital length of stay, mean GFR at timepoints 0 and 1 month, infectious complications, readmissions, biopsy proven rejection episodes, graft failure, and death, for a period of up to 1 year.

Results: The average age for patients in cohorts A and B were 16.4 and 12.5, respectively. 0 patients in cohort A were identified as high risk, as defined by a peak panel reactive antibody of greater than or equal to 20% or previous transplantation, while 3 patients in cohort B were identified as such. The hospital length of stay was 8.5 days versus 7.1 days between cohorts A and B. Mean GFR at the time of transplantation was 7 and 10 ml/min/1.73m2, compared to mean GFRs of 77 and 98ml/min/1.73m2 between cohorts A and B, respectively. Infectious complications occurred in 1/6 (16.7%) vs. 8/15 (53.3%) patients, and readmissions in 1/6 (16.7%) vs. 10/15(66.7%). Rejection episodes occurred in 0/6 (0%) and 2/15 (13.3%) patients. There were no episodes of graft failure or death in either group within one year.

Conclusions: Our preliminary experience using an induction regimen of rATG plus basiliximab in a pediatric patient population undergoing kidney transplantation suggests that the combination may be both safe and effective, although additional, larger studies with longer follow up is warranted.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Halleran D, Schurman S, Welch T, Whittaker V. Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/preliminary-results-of-a-novel-induction-regimen-using-anti-thymocyte-globulin-rabbit-ratg-plus-basiliximab-in-a-pediatric-patient-population-undergoing-kidney-transplantation/. Accessed May 30, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences